MX2023005081A - Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. - Google Patents

Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.

Info

Publication number
MX2023005081A
MX2023005081A MX2023005081A MX2023005081A MX2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A
Authority
MX
Mexico
Prior art keywords
methods
targeting
multispecific antibodies
antibodies
discovering
Prior art date
Application number
MX2023005081A
Other languages
English (en)
Inventor
David Campbell
Thomas R Diraimondo
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of MX2023005081A publication Critical patent/MX2023005081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan en la presente anticuerpos que se unen selectivamente a CD28 y PD-L1, composiciones farmacéuticas de los mismos, así como ácidos nucleicos, y métodos de uso, y métodos para fabricar y descubrir los mismos.
MX2023005081A 2020-10-30 2021-10-29 Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. MX2023005081A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063107942P 2020-10-30 2020-10-30
US202063123327P 2020-12-09 2020-12-09
US202063123329P 2020-12-09 2020-12-09
US202163141268P 2021-01-25 2021-01-25
US202163187690P 2021-05-12 2021-05-12
US202163187719P 2021-05-12 2021-05-12
US202163187699P 2021-05-12 2021-05-12
US202163189843P 2021-05-18 2021-05-18
PCT/US2021/057384 WO2022094299A2 (en) 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023005081A true MX2023005081A (es) 2023-06-15

Family

ID=81384468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005081A MX2023005081A (es) 2020-10-30 2021-10-29 Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.

Country Status (8)

Country Link
US (1) US20230406937A1 (es)
EP (1) EP4237013A2 (es)
JP (1) JP2023548443A (es)
KR (1) KR20230136913A (es)
AU (1) AU2021369835A1 (es)
CA (1) CA3196726A1 (es)
MX (1) MX2023005081A (es)
WO (1) WO2022094299A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
US11649286B2 (en) * 2017-06-25 2023-05-16 Systimmune Inc. Tri-specific antibodies
PE20211696A1 (es) * 2018-12-21 2021-09-01 Hoffmann La Roche Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
CA3134335A1 (en) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies

Also Published As

Publication number Publication date
CA3196726A1 (en) 2022-05-05
JP2023548443A (ja) 2023-11-16
EP4237013A2 (en) 2023-09-06
US20230406937A1 (en) 2023-12-21
WO2022094299A2 (en) 2022-05-05
AU2021369835A1 (en) 2023-06-01
KR20230136913A (ko) 2023-09-27
WO2022094299A3 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
WO2018234793A3 (en) Antibodies
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
NZ754051A (en) Novel antibodies and uses thereof
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
CL2019001517A1 (es) Anticuerpos y métodos de su utilización.
MY192392A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
MX2018016364A (es) Anticuerpos anti-pd-l1.
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP4218802A3 (en) Conjugates for targeted cell surface editing
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
MX2023005081A (es) Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2021005085A (es) Formulacion de anticuerpo.
WO2022084331A3 (en) Novel ligands for asialoglycoprotein receptor
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.